Piqray (Alpelisib) 150mg/200mg Tablets | Novartis Germany Original | GLT

Generic Information: Piqray (Alpelisib) — Novartis Germany Original

Piqray is the original Novartis alpelisib brand — the first PI3K alpha inhibitor ever approved for breast cancer, cleared by the US FDA in May 2019 and by the European medicines authorities the same year. The presentation GLT supplies is the German original: German-labeled Novartis cartons holding film-coated tablets in 150 mg and 200 mg strengths, including the combination packs used at reduced doses. German pharmaceutical packaging is among the most counterfeiting-resistant and widely recognized in the world, which is precisely why cross-border buyers ask for the DE presentation by name.

What Is Piqray (Alpelisib) Used For?

Piqray treats hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer in postmenopausal women and in men, taken together with the hormone therapy fulvestrant after the disease has progressed on a previous endocrine regimen. The PIK3CA detail is not fine print: roughly 40% of HR+/HER2- advanced breast cancers carry this mutation (Chinese series report close to half), and the mutation drives the PI3K/AKT/mTOR growth pathway that endocrine therapy alone can no longer restrain. A confirmed PIK3CA test result from tumor tissue or blood is therefore the gate to treatment — no mutation, no benefit.

How Does Piqray (Alpelisib) Work?

Alpelisib blocks the alpha isoform of phosphoinositide 3-kinase, the enzyme that mutated PIK3CA keeps switched on. Shutting that signal down slows proliferation and promotes death of the cancer cells that depend on the pathway, while the co-administered fulvestrant strips out the estrogen receptor that sustains them — the two mechanisms compound each other. In the pivotal SOLAR-1 trial this combination nearly doubled median progression-free survival in PIK3CA-mutated disease, lifting it from 5.7 months to 11.1 months, with overall survival extended by 7.9 months. That dataset remains the reference standard for the drug class.

Indications of Piqray (Germany)

The label covers, in plain terms: adults with HR-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer that progressed during or after endocrine therapy, treated in combination with fulvestrant. It does not extend to PIK3CA-wildtype disease, and it is a different product from Novartis' Vijoice brand, which carries the PROS (overgrowth syndrome) indication for the same molecule. German clinical practice follows the European label with the same mutation-testing precondition applied everywhere else.

Dosage and Administration

The standard dose is 300 mg once daily — two 150 mg tablets swallowed whole with food at about the same time each morning. On toxicity the dose steps down to 250 mg daily (one 200 mg plus one 50 mg tablet — the combination packs in the German presentation exist exactly for this step) and then to 200 mg daily (one 200 mg tablet); intolerance of the lowest step ends treatment. Fulvestrant runs on its own calendar: 500 mg intramuscularly on days 1, 15 and 29 of the first month, then once monthly. If a dose is missed it may be taken with food up to nine hours later; beyond that it is skipped, and vomiting is never followed by a re-dose. The practical packing math for buyers: at the standard dose a 150 mg 28-tablet carton covers 14 days, the 56-tablet carton covers 28 days, and the monthly requirement is 56 tablets of 150 mg.

Side Effects of Piqray

Hyperglycemia is the signature effect — alpelisib impairs insulin signalling, so fasting glucose and HbA1c are checked before starting and glucose is monitored through treatment, with anti-diabetic medication introduced if needed. Rash (including severe cutaneous reactions), diarrhea, stomatitis, fatigue, nausea and falling appetite are common; laboratory drifts in creatinine, glucose and liver enzymes are tracked on a standard schedule. Rare but serious risks are hypersensitivity, pneumonitis and severe skin reactions such as Stevens-Johnson syndrome — any blistering rash, breathlessness or persistent cough is an immediate-contact event. Contraception is mandatory during therapy and for at least a week after the last dose.

Storage Instructions

Store below 30°C in the original carton, protected from moisture and light — straightforward German-pack guidance that travels well. Do not remove tablets from the blister until the moment of use, keep the carton out of children's reach, and take expired tablets to a pharmacy for disposal.

Why Choose Piqray (DE) from GLT?

The German original answers the two questions serious buyers ask first: authenticity and price discipline. You receive sealed Novartis Germany cartons — German labeling, EU batch numbers, verifiable security printing — with batch documentation and pre-shipment photographs on request. And because GLT sources at European market terms rather than US list, the landed cost of the same month of therapy typically lands at a fraction of American pricing; we quote the exact figure up front with no games. Whether you are a family ordering one cycle or an institution running a tender, the line is open on WhatsApp +86 15234153837 and [email protected].

How to Order Piqray (Alpelisib)

Send the product name, pack sizes and quantity to WhatsApp +86 15234153837 or [email protected]. GLT returns a formal quotation with courier and payment options, typically within one working day; after confirmation we dispatch with complete export paperwork, and standing monthly orders are scheduled so treatment never pauses. Institutional buyers can request CoA and batch images before paying.

FAQ

How is Piqray Germany different from Pivikto or LuciAlpe? Piqray is the Novartis original with EU/German packaging; Pivikto is the same company's India-market brand; LuciAlpe is a Lao generic by Lucius. Molecule and evidence base are shared — packaging, price and paperwork differ, and we will quote them side by side.

How many tablets do I need per month? At the standard 300 mg dose: 56 tablets of 150 mg — one 56-tablet carton or two 28-tablet cartons, taken as two tablets every morning with food.

Why must PIK3CA testing come first? Benefit in trials was confined to mutation carriers; testing tissue or blood (ctDNA) before starting is standard practice and protects you from paying for a drug that cannot work.

Can Piqray be used for PROS? No — the PROS indication belongs to the Vijoice brand, dosed entirely differently. The two brands are not interchangeable.

What if blood sugar rises on treatment? It is the most expected effect; your oncologist monitors fasting glucose, adds or optimizes anti-diabetic medication, and only in severe cases interrupts or stops alpelisib.